Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sulfadoxine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet
Details : Sulfadoxine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2024
Lead Product(s) : Sulfadoxine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable